{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027751","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.434510+00:00","generated_at":"2026-06-21T15:36:37.607427+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Diffusion Pharmaceuticals in active bidding stage, rejects LifeSci unsolicited bid; proxy contest looms","bullets":["Board rejected unsolicited offer from LifeSci Capital client as 'woefully inadequate' and encouraged participation in strategic review.","LifeSci-affiliated fund commenced proxy contest to replace Board nominees; Company says it lacks relevant industry expertise.","Strategic review process at active bidding stage with multiple parties; Canaccord Genuity and Dechert LLP advising.","2022 Annual Meeting set for December 30, 2022, two weeks later than previously announced to focus on strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027751","json":"https://secwatch.observer/filing/0001437749-22-027751.json","markdown":"https://secwatch.observer/filing/0001437749-22-027751.md","text":"https://secwatch.observer/filing/0001437749-22-027751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922027751/0001437749-22-027751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922027751/dffn20221117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:36:37.607427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ef5acc2bb50edb56f762b15a2a77999391de495","claim":"CervoMed Inc. reported financial results for the three-month period ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Diffusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing financial results for the three-month period ended September 30, 2022 and a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922027751/0001437749-22-027751-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month period ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}